US20150005488A1 - Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids - Google Patents

Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids Download PDF

Info

Publication number
US20150005488A1
US20150005488A1 US14/487,662 US201414487662A US2015005488A1 US 20150005488 A1 US20150005488 A1 US 20150005488A1 US 201414487662 A US201414487662 A US 201414487662A US 2015005488 A1 US2015005488 A1 US 2015005488A1
Authority
US
United States
Prior art keywords
hydrogen
formula
compound
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/487,662
Inventor
Claus Christian Haeselhoff
Mike Petersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40029248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20150005488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Priority to US14/487,662 priority Critical patent/US20150005488A1/en
Assigned to BAYER INTELLECTUAL PROPERTY GMBH reassignment BAYER INTELLECTUAL PROPERTY GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAESELHOFF, CLAUS CHRISTIAN, PETERSEN, MIKE
Publication of US20150005488A1 publication Critical patent/US20150005488A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • C07J53/0043 membered carbocyclic rings
    • C07J53/0083 membered carbocyclic rings in position 15/16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a process for the preparation of 17 ⁇ -(3-hydroxypropyl)-17 ⁇ -hydroxysteroids, the intermediates of the process as such, a process for their preparation and the use of the intermediates for the preparation of steroid 21,17-spirolactones, in particular drospirenone.
  • pharmacologically active steroid 21,17-carbolactones such as, for example, of eplerenone (9 ⁇ ,11 ⁇ -epoxy-7 ⁇ -methoxy-carbonyl-3-oxo-17 ⁇ -pregn-4-ene-21,17-carbolactone), drospirenone (6 ⁇ ,7 ⁇ ;15 ⁇ ,16 ⁇ -dimethylene-3-oxo-17 ⁇ -pregn-4-ene-21,17-carbolactone, spironolactone (7 ⁇ -acetylthio-3-oxo-17 ⁇ -pregn-4-ene-21,17-carbolactone, canrenone (3-oxo-17 ⁇ -pregna-4,6-diene-21,17-carbolactone) and prorenone (6 ⁇ ,7 ⁇ -methylene-3-oxo-17 ⁇ -pregn-4-ene-21,17-carbolactone).
  • eplerenone (9 ⁇ ,11 ⁇ -epoxy-7 ⁇ -methoxy-carbonyl-3-oxo-17 ⁇
  • Suitable oxidants such as chromic acid (Sam et al. J. Med. Chem. 1995, 38, 4518-4528), pyridinium chlorochromate (EP 075189), pyridinium dichromate (Bittler et al; Angew. Chem. 1982, 94, 718-719; Nickisch et al. Liebigs Ann. Chem. 1988, 579-584), potassium bromate in the presence of a ruthenium catalyst (EP 918791) or with an alkali metal or alkaline earth metal hypochlorite in the presence of a TEMPO catalyst (WO 2007/009821); and optionally after acid-catalysed elimination of water.
  • suitable oxidants such as chromic acid (Sam et al. J. Med. Chem. 1995, 38, 4518-4528), pyridinium chlorochromate (EP 075189), pyridinium dichromate (Bittler et al; Angew. Chem.
  • 17-(3-Hydroxypropyl)-17-hydroxysteroids can be prepared by the hydrogenation of 17-(3-hydroxy-1-propynyl)-17-hydroxysteroids.
  • the synthesis of the 17-(3-hydroxy-1-propynyl)-17-hydroxysteroids is carried out by the base-induced addition of prop-1-yn-3-ol to the corresponding 17-ketosteroids [Bittler et al.; Angew. Chem. 1982, 94, 718-719; Nickisch et al.; J. Med. Chem. 1987, 30, 1403-1409; EP 075189 B1].
  • the object of the present invention therefore consists in making available an alternative process for the preparation of 17 ⁇ -(3-hydroxypropyl)-17 ⁇ -hydroxysteroids of the formula I from the corresponding 17-ketosteroids of the formula III, which makes it possible to prepare the target compounds in higher yield and purity.
  • Suitable bases for the addition of the propynol ether (step a) are alkali metal or alkaline earth metal alkoxides. Alkali metal methoxides, ethoxides and tert-butoxides are preferred. Potassium tert-butoxide (KOtBu) in THF as a solvent has proven particularly suitable. The addition is preferably carried out in a temperature range from 0° C. to 50° C.
  • the compounds of the formula V are reacted with hydrogen as a solution or suspension according to known methods in the presence of a transition metal catalyst [V. Jäger and H. G. Viehe in “Methoden der organischen Chemie” [Methods of Organic Chemistry] (Houben-Weyl), Volume V/2a, pp. 693-700].
  • the hydrogenation product can subsequently be debenzylated with hydrogen, without isolation or purification being necessary, either in the presence of, for example, Pd/carbon [Larcheveque et al., Tetrahedron; 1988, 44, 6407-6418] or else by Birch reduction [Itoh et al., Tetrahedron Lett.; 1986; 27, 5405-5408] to give the compounds of the formula I.
  • the catalyst used for the hydrogenation of the alkyne function is preferably Raney nickel or palladium on various carrier materials.
  • the catalytic debenzylation is carried out in the presence of suitable transition metal hydrogenation catalysts, preferably Pd/carbon or Pd(OH) 2 /carbon.
  • suitable solvents for this step are protic solvents such as, for example, ethanol.
  • the removal of the benzyl group can also be carried out by Birch reduction.
  • the hydrogenation product is reacted in an inert solvent mixture with alkali metals (lithium, sodium, potassium) or alkaline earth metals (calcium).
  • the solvent used is a mixture of liquid NH 3 or a primary amine and an ethereal solvent (tetrahydrofuran, diethyl ether, dimethoxyethane, diglyme etc). Lithium or sodium is preferred as a reductant.
  • the Birch reduction is very preferably carried out with lithium in a solvent mixture of liquid NH 3 and dimethoxyethane.
  • the present invention further also relates to the compounds of the formula V as intermediates and to the process for their preparation, namely a process for the preparation of compounds of the formula V
  • R 40 , R 41 , R 42 independently of one another are hydrogen, namely with the prop-1-yn-3-ol-benzyl ether IVa
  • R 5 is hydrogen or hydroxyl
  • R 6 is hydrogen or together with R 7 is an ⁇ or ⁇ —CH 2 group
  • R 7 is hydrogen or an ⁇ or ⁇ —CH 2 group
  • R 10 is hydrogen, methyl or ethyl
  • R 13 is methyl, ethyl
  • R 15 is hydrogen, C 1 -C 4 -alkyl, or together with R 16 is a —CH 2 group
  • R 16 is hydrogen or together with R 15 is a —CH 2 group, are employed.
  • a particularly preferred process according to the present invention is the process for the preparation of the compound Ia,
  • step a) in which in which in step a) compound IIIa
  • a very particularly preferred process according to the present invention is the process for the preparation of the compound Ia,
  • step a) the compound IIIa
  • Compound Ia is obtained in high purity with a total yield of 91% of theory and can be reacted without further purification according to known methods to give compound IIa (drospirenone) [EP 075189 B1, EP 918791 B1, WO 2007/009821].
  • the total yield of drospirenone is increased by at least 15%.
  • the high purity of the intermediate Ia obtained in the process according to the invention leads to further process advantages (no intermediate isolation).
  • an alkali metal or alkaline earth metal alkoxide preferably potassium tert-butoxide
  • 606.1 mmol of an alkali metal or alkaline earth metal alkoxide, preferably potassium tert-butoxide are dissolved in 120 ml of tetrahydrofuran.
  • a solution or suspension of 121.2 mmol of a compound of the formula I or II and 133.3 mmol of a propynol ether of the formula III in 520 ml of tetrahydrofuran is metered into the mixture at ⁇ 20 to 50° C., preferably at 0 to 5° C.
  • the reaction mixture is treated with 280 ml of water and subsequently rendered neutral by addition of acid, preferably acetic acid.
  • the aqueous phase is separated off and discarded.
  • IR: 3390 (O—H, stretching oscillation of alcohols), 3088, 3018 (C—H, stretching oscillation of aromatic and olefinic hydrocarbon), 2937, 2867 (C—H, stretching oscillation of aliphatic hydrocarbon), 2225 (C ⁇ C, stretching oscillation of alkyne), 1052 (C—O, stretching oscillation of alcohols), 739 ( ⁇ C—H, deformation oscillation of aromatic or olefinic hydrocarbon)
  • IR: 3480, 3425 cm ⁇ 1 (O—H); 3119, 3025 cm ⁇ 1 (C—H, stretching oscillation of aromatic and olefinic hydrocarbon); 2950 cm ⁇ 1 (C—H, stretching oscillation of aliphatic hydrocarbon); 2225 cm ⁇ 1 (C ⁇ C, stretching oscillation of alkyne); 1055 cm ⁇ 1 (C—O, stretching oscillation of alcohols).
  • reaction mixture After warming the reaction mixture to 20° C., the latter is added to a solution of 76 ml of acetic acid in 1320 ml of water and the mixture is neutralized by addition of further acetic acid and then freed of dimethoxyethane and methanol by vacuum distillation. The precipitated solid is isolated, washed with water and dried at 50° C.
  • the filtrate prepared according to GWP2 is freed completely of solvent by distillation.
  • the distillation residue is taken up in 660 ml of ethanol and 2% by weight of Pd(OH) 2 /C (15-20%) are added.
  • the mixture is reacted with hydrogen at 20° C. and a pressure of 3 bar.
  • the catalyst is separated off by filtration.
  • ethanol is removed by distillation. The precipitated solid is isolated, washed with water and dried at 50° C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a process for the preparation of 17α-(3-hydroxypropyl)-17β-hydroxysteroids of the formula I
Figure US20150005488A1-20150101-C00001
starting from 17-ketosteroids of the formula III
Figure US20150005488A1-20150101-C00002
via the intermediates of the formula V
Figure US20150005488A1-20150101-C00003
wherein the radicals R3, R5, R6, R7, R10, R13, R15, R16, R40, R41 and R42 have the meaning indicated in the description.

Description

  • This application claims the benefit of the filing date of U.S. Provisional Application Ser. No. 60/946,762 filed Jun. 28, 2007.
  • The present invention relates to a process for the preparation of 17α-(3-hydroxypropyl)-17β-hydroxysteroids, the intermediates of the process as such, a process for their preparation and the use of the intermediates for the preparation of steroid 21,17-spirolactones, in particular drospirenone.
  • 17α-(3-Hydroxypropyl)-17β-hydroxysteroids of the formula I
  • Figure US20150005488A1-20150101-C00004
  • serve as starting substances for the synthesis of pharmacologically active steroid 21,17-carbolactones, such as, for example, of eplerenone (9α,11α-epoxy-7α-methoxy-carbonyl-3-oxo-17α-pregn-4-ene-21,17-carbolactone), drospirenone (6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, spironolactone (7α-acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone, canrenone (3-oxo-17α-pregna-4,6-diene-21,17-carbolactone) and prorenone (6β,7β-methylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone).
  • The synthesis of such steroid 21,17-spirolactones is carried out by the oxidation of the corresponding 17α-(3-hydroxypropyl)-17β-hydroxysteroids
  • Figure US20150005488A1-20150101-C00005
  • using suitable oxidants such as chromic acid (Sam et al. J. Med. Chem. 1995, 38, 4518-4528), pyridinium chlorochromate (EP 075189), pyridinium dichromate (Bittler et al; Angew. Chem. 1982, 94, 718-719; Nickisch et al. Liebigs Ann. Chem. 1988, 579-584), potassium bromate in the presence of a ruthenium catalyst (EP 918791) or with an alkali metal or alkaline earth metal hypochlorite in the presence of a TEMPO catalyst (WO 2007/009821); and optionally after acid-catalysed elimination of water.
  • 17-(3-Hydroxypropyl)-17-hydroxysteroids can be prepared by the hydrogenation of 17-(3-hydroxy-1-propynyl)-17-hydroxysteroids. The synthesis of the 17-(3-hydroxy-1-propynyl)-17-hydroxysteroids is carried out by the base-induced addition of prop-1-yn-3-ol to the corresponding 17-ketosteroids [Bittler et al.; Angew. Chem. 1982, 94, 718-719; Nickisch et al.; J. Med. Chem. 1987, 30, 1403-1409; EP 075189 B1].
  • Figure US20150005488A1-20150101-C00006
  • A disadvantage in the use of prop-1-yn-3-ol (propargyl alcohol) as a functionalized C3 structural unit is the distinctly pronounced byproduct formation (in particular 17-ethynyl steroids) caused by its instability to bases.
  • The instability of propargyl alcohol all in all leads to an obstacle to the isolation of the pure product and to a decrease in the yield.
  • The object of the present invention therefore consists in making available an alternative process for the preparation of 17α-(3-hydroxypropyl)-17β-hydroxysteroids of the formula I from the corresponding 17-ketosteroids of the formula III, which makes it possible to prepare the target compounds in higher yield and purity.
  • This object has been achieved according to the invention by a process for the preparation of 17α-(3-hydroxypropyl)-17β-hydroxysteroids of the formula I,
  • Figure US20150005488A1-20150101-C00007
  • which comprises the following steps:
    • a) reaction of 17-ketosteroids of the formula III
  • Figure US20150005488A1-20150101-C00008
  • wherein
    • R3 can be hydrogen or the group
  • Figure US20150005488A1-20150101-C00009
  • wherein
    • R30, R31, R32 independently of one another can be hydrogen, C1-C4-alkyl or C1-C4-alkoxy;
    • R5 can be hydrogen, hydroxyl or together with R6 can be a double bond;
    • R6 can be hydrogen, together with R5 or R7 can be a double bond; or together with R7 can be an α or β —CH2 group;
    • R7 can be hydrogen, C1-C4-alkyl, C1-C4-alkoxycarbonyl, C1-C4-thioacyl; together with R6 can be a double bond or an α or β —CH2 group;
    • R10 can be hydrogen, methyl or ethyl;
    • R13 can be methyl, ethyl;
    • R15 can be hydrogen, C1-C4-alkyl, or together with R16 can be a —CH2 group or a double bond;
    • R16 can be hydrogen or together with R15 can be a —CH2 group or a double bond,
      • in the presence of a base,
      • with a prop-1-yn-3-ol ether of the formula IV
  • Figure US20150005488A1-20150101-C00010
  • wherein
    • R40, R41, R42 independently of one another can be hydrogen, C1-C4-alkyl or C1-C4-alkoxy;
      • to give compounds of the general formula V
  • Figure US20150005488A1-20150101-C00011
    • b) complete catalytic hydrogenation of the alkyne function of the compound V, and
    • c) removal of the benzylic protective group.
  • Suitable bases for the addition of the propynol ether (step a) are alkali metal or alkaline earth metal alkoxides. Alkali metal methoxides, ethoxides and tert-butoxides are preferred. Potassium tert-butoxide (KOtBu) in THF as a solvent has proven particularly suitable. The addition is preferably carried out in a temperature range from 0° C. to 50° C.
  • For the purpose of complete hydrogenation of the alkyne function, the compounds of the formula V are reacted with hydrogen as a solution or suspension according to known methods in the presence of a transition metal catalyst [V. Jäger and H. G. Viehe in “Methoden der organischen Chemie” [Methods of Organic Chemistry] (Houben-Weyl), Volume V/2a, pp. 693-700]. The hydrogenation product can subsequently be debenzylated with hydrogen, without isolation or purification being necessary, either in the presence of, for example, Pd/carbon [Larcheveque et al., Tetrahedron; 1988, 44, 6407-6418] or else by Birch reduction [Itoh et al., Tetrahedron Lett.; 1986; 27, 5405-5408] to give the compounds of the formula I.
  • The catalyst used for the hydrogenation of the alkyne function is preferably Raney nickel or palladium on various carrier materials.
  • The catalytic debenzylation is carried out in the presence of suitable transition metal hydrogenation catalysts, preferably Pd/carbon or Pd(OH)2/carbon. Particularly suitable solvents for this step are protic solvents such as, for example, ethanol.
  • Alternatively to hydrogenating debenzylation, the removal of the benzyl group can also be carried out by Birch reduction. For this, the hydrogenation product is reacted in an inert solvent mixture with alkali metals (lithium, sodium, potassium) or alkaline earth metals (calcium). Preferably, the solvent used is a mixture of liquid NH3 or a primary amine and an ethereal solvent (tetrahydrofuran, diethyl ether, dimethoxyethane, diglyme etc). Lithium or sodium is preferred as a reductant. According to the invention, the Birch reduction is very preferably carried out with lithium in a solvent mixture of liquid NH3 and dimethoxyethane.
  • The yield of compounds of the formula I from the Birch reduction is comparable with that from catalytic debenzylation.
  • The present invention further also relates to the compounds of the formula V as intermediates and to the process for their preparation, namely a process for the preparation of compounds of the formula V
  • Figure US20150005488A1-20150101-C00012
  • comprising the following step
    • a) reaction of 17-ketosteroids of the formula III
  • Figure US20150005488A1-20150101-C00013
  • wherein
    • R3 can be hydrogen or the group
  • Figure US20150005488A1-20150101-C00014
  • wherein
    • R30, R31, R32 independently of one another can be hydrogen, C1-C4-alkyl or C1-C4-alkoxy;
    • R5 can be hydrogen, hydroxyl or together with R6 can be a double bond;
    • R6 can be hydrogen, together with R5 or R7 can be a double bond; or together with R7 can be an α or β —CH2 group;
    • R7 can be hydrogen, C1-C4-alkyl, C1-C4-alkoxycarbonyl, C1-C4-thioacyl; together with R6 can be a double bond or an α or β —CH2 group;
    • R10 can be hydrogen, methyl or ethyl;
    • R13 can be methyl, ethyl;
    • R15 can be hydrogen, C1-C4-alkyl, or together with R16 can be a —CH2 group or a double bond;
    • R16 can be hydrogen or together with R15 can be a —CH2 group or a double bond,
      • in the presence of a base,
      • with a prop-1-yn-3-ol ether of the formula IV
  • Figure US20150005488A1-20150101-C00015
  • wherein
    • R40, R41, R42 independently of one another can be hydrogen, C1-C4-alkyl or C1-C4-alkoxy.
  • According to the present invention, the process in which 17-ketosteroids of the formula III are reacted with a prop-1-yn-3-ol ether of the formula IV
  • wherein
    R40, R41, R42 independently of one another are hydrogen,
    namely with the prop-1-yn-3-ol-benzyl ether IVa
  • Figure US20150005488A1-20150101-C00016
  • is preferred.
  • The process according to the invention for the preparation of the compounds of the formula I is particularly suitable and therefore preferred in which process compounds of the formula III,
  • wherein
    R5 is hydrogen or hydroxyl;
    R6 is hydrogen or together with R7 is an α or β —CH2 group;
    R7 is hydrogen or an α or β —CH2 group;
    R10 is hydrogen, methyl or ethyl;
    R13 is methyl, ethyl;
    R15 is hydrogen, C1-C4-alkyl, or together with R16 is a —CH2 group;
    R16 is hydrogen or together with R15 is a —CH2 group, are employed.
  • A particularly preferred process according to the present invention is the process for the preparation of the compound Ia,
  • Figure US20150005488A1-20150101-C00017
  • in which in step a) compound IIIa
  • Figure US20150005488A1-20150101-C00018
  • is reacted to give Va
  • Figure US20150005488A1-20150101-C00019
  • and is reacted further in the steps b) and c).
  • A very particularly preferred process according to the present invention is the process for the preparation of the compound Ia,
  • Figure US20150005488A1-20150101-C00020
  • in which in step a) the compound IIIa
  • Figure US20150005488A1-20150101-C00021
  • is reacted in the presence of a base,
    with the prop-1-yn-3-ol ether of the formula IVa
  • Figure US20150005488A1-20150101-C00022
  • to give the compound Vb
  • Figure US20150005488A1-20150101-C00023
  • and is reacted further in the steps b) and c) to give the compound Ia.
  • TABLE 1
    Comparison of the yields of the process according to the invention
    compared to processes of the prior art
    Process/reagent in step Yield (% of theory)
    a) IIIa → Vb Vb → Ia Total (IIIa → Ia)
    process according to the 92 99 91
    invention/
    IVa
    EP 75189/prop-1-yn-3-ol 75* 99 74
    *the 17α-(3-hydroxyl-1-propynyl) derivative
  • Compound Ia is obtained in high purity with a total yield of 91% of theory and can be reacted without further purification according to known methods to give compound IIa (drospirenone) [EP 075189 B1, EP 918791 B1, WO 2007/009821].
  • Figure US20150005488A1-20150101-C00024
  • Reference is made explicitly here to Example H on p. 5, I. 25-32 in EP 075189B1; the examples of p. 5, I. 56-58 to p. 6, I. 1-22 in EP 0918791 B1 and the examples on pp. 12-15 and the entire disclosure content in WO 2007/009821. The processes for the reaction of the compound Ib to give drospirenone (compound IIa) described therein belong to the disclosure content of the present patent application.
  • By the use of the intermediates Va or Vb for the preparation of drospirenone, the total yield of drospirenone is increased by at least 15%. The high purity of the intermediate Ia obtained in the process according to the invention leads to further process advantages (no intermediate isolation).
  • PREPARATION PROCESSES General Working Procedure 1 (GWP1): Synthesis of Compounds of the Formula V
  • 606.1 mmol of an alkali metal or alkaline earth metal alkoxide, preferably potassium tert-butoxide, are dissolved in 120 ml of tetrahydrofuran. A solution or suspension of 121.2 mmol of a compound of the formula I or II and 133.3 mmol of a propynol ether of the formula III in 520 ml of tetrahydrofuran is metered into the mixture at −20 to 50° C., preferably at 0 to 5° C. After reaction is complete, the reaction mixture is treated with 280 ml of water and subsequently rendered neutral by addition of acid, preferably acetic acid. The aqueous phase is separated off and discarded.
  • The crude products obtained after evaporation of tetrahydrofuran are recrystallized from a suitable solvent and dried.
  • EXAMPLE 1 6β,7β;15β,16β-Dimethylene-17α-(3-benzyloxypropynyl)androstane-3β,5β,17β-triol (VB)
  • According to GWP1, 100 g (0.303 mol) of 3β,5β-dihydroxy-6β,7β;15β,16β-dimeth-yleneandrostan-17-one were reacted with 48.7 g (0.333 mol) of prop-1-yn-3-ol benzyl ether.
  • The crude product was recrystallized from 700 ml of toluene. 133 g (0.279 mol) of 6β,7β;15γ,16β-dimethylene-17α-(3-benzyloxypropynyl)androstane-3β,5β,17β-triol=92% of theory were obtained.
  • [α]D 20=−70.1° (CHCl3, 12.15 mg in 1 ml of solution, T=20° C., d=100 mm).
  • 1H-NMR (400 MHz, CDCl3): δ=0.37-0.42 (1H, m, H-30 exo*), 0.63 (1H, td, J=9.0 Hz and 5.1 Hz, H-31 endo), 0.78 (1H, q, J=5.1 Hz, H-31 endo), 0.82-0.88 (1H, m, H-6), 0.85 (3H, s, H-19), 0.91 (3H, s, H-18), 1.13 (1H, tt, J=8.4 Hz and 4.3 Hz, H-7), 1.15-1.27 (4H, m, H-30 exo, H-1, H-9, H-11), 1.39-1.44 (1H, m, H-2α), 1.46-1.54 (3H, m, H-11, H-12β, H-15), 1.57 (1H, dt, J=13.6 Hz and 2.9 Hz, H-2β), 1.66-1.74 (3H, m, H-12α, H-16, H-8), 1.84 (1H, td, J=14.5 Hz and 2.9 Hz, H-1β), 1.96-2.01 (1H, m, H-4β), 2.04 (1H, dd, J=12.1 Hz and 3.7 Hz, H-1), 2.23 (1H, dd, J=15.0 Hz and 3.3 Hz, H-4α), 2.15-2.35, 2.55-2.70, 3.25-3.50 (3H, strongly broadened, 3 times OH), 4.03 (1H, s, br., H-3), 4.30 (2H, s, H-22), 4.64 (2H, s, H-23), 7.29-7.38 (5H, m, H-25, H-26, H-27, H-28, H-29)
  • 13C-NMR (400 MHz, CDCl3): δ=8.97 (CH2, C-30), 11.69 (CH2, C-31), 15.20 (CH, C-7), 16.67 (CH, C-15), 18.26 (CH3, C-18), 19.04 (CH3, C-19), 21.79 (CH2, C-11), 25.34 (CH, C-6), 26.81 (CH2, C-1), 27.06 (CH, C-16), 27.69 (CH2, C-2), 34.20 (CH, C-8), 38.62 (CH2, C-12), 40.42 (C, C-10), 42.65 (C, C-13), 43.04 (CH2, C-4), 44.59 (CH, C-9), 52.88 (CH, C-14), 57.63 (CH2, C-22), 67.09 (CH, C-3), 71.59 (CH2, C-23), 74.84 (C, C-5), 79.80 (C, C-17), 82.06 (C, C-21), 88.99 (C, C-20), 127.93 (CH, C-27), 128.06 (CH, C-26, C-28), 128.44 (CH, C-25, C-29), 137.40 (C, C-24)
  • MS (Cl): m/e=476 (M+NH4-H2O)+, 459 (M+H-H2O)+, 441 (459-H2O), 348 (M+NH4-C10H10O)+, 331 (476-C10H9O), 313 (331-H2O), 295 (313-H2O), 164 (C11H16O+), 91 (C7H7 +)
  • IR:
    Figure US20150005488A1-20150101-P00001
    =3390 (O—H, stretching oscillation of alcohols), 3088, 3018 (C—H, stretching oscillation of aromatic and olefinic hydrocarbon), 2937, 2867 (C—H, stretching oscillation of aliphatic hydrocarbon), 2225 (C≡C, stretching oscillation of alkyne), 1052 (C—O, stretching oscillation of alcohols), 739 (═C—H, deformation oscillation of aromatic or olefinic hydrocarbon)
  • EXAMPLE 2 15β,16β-Methylene-17α-(3-benzyloxypropynyl)androst-6-ene-3β, 5β,17β-triol
  • According to GWP1, 100 g (0.317 mol) of 3β,5β-dihydroxy-15β,16β-methylene-androst-6-en-17-one were reacted with 50.9 g (0.349 mol) of prop-1-yn-3-ol benzyl ether.
  • The crude product was recrystallized from 700 ml of toluene. 134.5 g (0.291 mol) of 15β,16β-methylene-17α-(3-benzyloxypropynyl)androst-6-ene-5β,17β-diol=92% of theory were obtained.
  • [α]D 20=−120.3° (CHCl3, 12.15 mg in 1 ml of solution, T=20° C., d=100 mm)
  • 1H-NMR (400 MHz, CDCl3): δ=0.35-0.42 (1H, m, H-30 exo), 0.95 (3H, s, H-18), 0.96 (3H, s, H-19), 1.14 (1H, ddd J=6.8 Hz, 3.7 Hz and 3.5 Hz, H-30 endo*), 1.28-1.35 (1H, m, H-11β), 1.38-1.42 (1H, m, H-15), 1.45-1.51 (2H, m, H-1β, H-2), 1.50-1.60 (3H, m, H-12β, H-11α, H-9), 1.60-1.65 (1H, m, H-2), 1.67-1.73 (2H, m, H-16, H-12α), 1.83-1.89 (1H, m, H-1α), 1.88-1.97 (3H, m, both H-4, H-14), 2.15-2.19 (1H, m, H-8), 2.25-2.40, 2.90-3.10, 3.05-3.25 (3H, strongly broadened, 3 times OH), 4.04-4.07 (1H, m, H-3), 4.28 (2H, s, H-22), 4.62 (2H, s, H-23), 5.49 (1H, dd J=10.0 Hz and 2.8 Hz, H-6), 5.68 (1H, dd J=10.0 Hz and 1.8 Hz, H-7), 7.29-7.36 (5H, m, H-25, H-26, H-27, H-28, H-29)
  • 13C-NMR (400 MHz, CDCl3): δ=8.90 (CH2, C-30), 16.25 (CH, C-15), 18.05 (CH3, C-19), 18.28 (CH3, C-18), 21.12 (CH2, C-11), 24.73 (CH2, C-1), 27.31 (CH, C-16), 27.89 (CH2, C-2), 36.53 (CH, C-8), 38.77 (CH2, C-12), 39.12 (C, C-10), 40.68 (CH2, C-4), 42.86 (C, C-13), 43.99 (CH, C-9), 51.27 (CH, C-14), 57.59 (CH2, C-22), 67.31 (CH, C-3), 71.56 (CH2, C-23), 75.93 (C, C-5), 79.71 (C, C-17), 82.13 (C, C-21), 88.88 (C, C-20), 127.93 (CH, C-27), 128.02 (CH, C-7), 128.05 (CH, C-26, C-28), 128.44 (CH, C-25, C-29), 134.52 (CH, C-6), 137.35 (C, C-24)
  • MS (Cl): m/e=480 (M+NH4)+, 462 (480-H2O), 445 (M+H)+, 427 (445-H2O), 334 (480-C10H10O), 317 (462-C10H9O), 299 (317-H2O), 281 (299-H2O), 244 (C17H24O+), 164 (C11H16O+), 91 (C7H7 +)
  • IR:
    Figure US20150005488A1-20150101-P00001
    =3480, 3425 cm−1 (O—H); 3119, 3025 cm−1 (C—H, stretching oscillation of aromatic and olefinic hydrocarbon); 2950 cm−1 (C—H, stretching oscillation of aliphatic hydrocarbon); 2225 cm−1 (C≡C, stretching oscillation of alkyne); 1055 cm−1 (C—O, stretching oscillation of alcohols).
  • General Working Procedure 2 (GWP2): Hydrogenation and Birch Reduction of the Compounds of the Formula V to Compounds of the Formula I
  • 277 mmol of a compound of the formula V are dissolved in 924 ml of dimethoxyethane and treated with 1.7% by weight of Pd/C (10%). The mixture is first reacted with hydrogen at 20° C. and a pressure of 3 bar. After absorption of hydrogen is complete, the reaction mixture is warmed to 50° C. and stirred until the end of gas absorption. The catalyst is removed by filtration. The filtrate is metered at −40° C. into a solution prepared from 396 ml of dimethoxyethane, 699 ml of NH3 and at least 1664 mmol of lithium. Subsequently, 406 ml of methanol are added in portions. After warming the reaction mixture to 20° C., the latter is added to a solution of 76 ml of acetic acid in 1320 ml of water and the mixture is neutralized by addition of further acetic acid and then freed of dimethoxyethane and methanol by vacuum distillation. The precipitated solid is isolated, washed with water and dried at 50° C.
  • General Working Procedure 3 (GWP3): Hydrogenation and Hydrogenating Debenzylation of the Compounds of the Formula V to Compounds of the Formula I
  • The filtrate prepared according to GWP2 is freed completely of solvent by distillation. The distillation residue is taken up in 660 ml of ethanol and 2% by weight of Pd(OH)2/C (15-20%) are added. The mixture is reacted with hydrogen at 20° C. and a pressure of 3 bar. After absorption of hydrogen is complete, the catalyst is separated off by filtration. After addition of 660 ml of water, ethanol is removed by distillation. The precipitated solid is isolated, washed with water and dried at 50° C.
  • EXAMPLE 3 6β,7β;15β,16β-Dimethylene-17α-(3-hydroxypropyl)androstane-3β, 5β,17β-triol (Ia)
  • 100 g (0.210 mol) of 6β,7β;15β,16β-dimethylene-17α-(3-benzyloxypropynyl)androstane-3β,5β,17β-triol were reacted according to GWP2 or GWP3. 81.1 g (0.208 mol) of 6β,7β;15β,16β-dimethylene-17α-(3-hydroxypropyl)androstane-3β,5β,17β-triol=99% of theory were obtained.
  • MS (Cl): m/e=389 (M−H)+, 373 (M+H-H2O)+, 355 (373-H2O), 337 (355-H2O), 319 (337-H2O).
  • Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The preceding preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
  • In the foregoing and in the examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated.
  • The entire disclosures of all applications, patents and publications, cited herein and of corresponding German application No. 10 2007 030 596.8, filed Jun. 28, 2007, are incorporated by reference herein.
  • The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
  • From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims (17)

1-13. (canceled)
14. A process for preparing a compound of formula II
Figure US20150005488A1-20150101-C00025
comprising oxidizing a compound of formula I
Figure US20150005488A1-20150101-C00026
which compound of formula I has been synthesized by the complete catalytic hydrogenation of the alkyne function of a compound of formula V
Figure US20150005488A1-20150101-C00027
and by removal of the benzylic protective group or groups,
wherein in the compounds of formulas I, II and V
R3 is hydrogen or
Figure US20150005488A1-20150101-C00028
R30, R31, R32 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy;
R5 is hydrogen, or hydroxyl or together with R6 can be a double bond;
R6 is hydrogen, or together with R5 or R7 is a double bond; or together with R7 is an α or β-CH2 group;
R7 is hydrogen, C1-C4-alkyl, C1-C4-alkoxycarbonyl, C1-C4-thioacyl; or together with R6 is a double bond or an α or β-CH2 group;
R10 is hydrogen, methyl or ethyl;
R13 is methyl, or ethyl;
R15 is hydrogen, or C1-C4-alkyl, or together with R16 is a —CH2 group or a double bond;
R16 is hydrogen or together with R15 is a —CH2 group or a double bond, and
R40, R41, R42 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy.
15. A process according to claim 14, wherein a compound of formula I has been synthesized by the complete catalytic hydrogenation of the alkyne function of a compound of formula Va
Figure US20150005488A1-20150101-C00029
wherein
R3 is hydrogen or
Figure US20150005488A1-20150101-C00030
R30, R31, R32 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy; and
R40, R41, R42 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy;
and by removal of the benzylic protective group or groups.
16. A process according to claim 14, which is for the preparation of a compound of formula IIa
Figure US20150005488A1-20150101-C00031
comprising oxidizing a compound of formula Ia
Figure US20150005488A1-20150101-C00032
which compound of formula Ia has been synthesized by the complete catalytic hydrogenation of the alkyne function of a compound of formula Vb
Figure US20150005488A1-20150101-C00033
and by removal of the benzylic protective group.
17. A process according to claim 14, wherein the compound of formula II is drospirenone.
18. A process according to claim 15, wherein the compound of formula II is drospirenone.
19. A process in which a reaction of a compound of formula V
Figure US20150005488A1-20150101-C00034
wherein
R3 is hydrogen or
Figure US20150005488A1-20150101-C00035
R30, R31, R32 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy;
R5 is hydrogen, or hydroxyl or together with R6 can be a double bond;
R6 is hydrogen, or together with R5 or R7 is a double bond; or together with R7 is an α or β-CH2 group;
R7 is hydrogen, C1-C4-alkyl, C1-C4-alkoxycarbonyl, C1-C4-thioacyl; or together with R6 is a double bond or an α or β-CH2 group;
R10 is hydrogen, methyl or ethyl;
R13 is methyl, or ethyl;
R15 is hydrogen, or C1-C4-alkyl, or together with R16 is a —CH2 group or a double bond;
R16 is hydrogen or together with R15 is a —CH2 group or a double bond, and
R40, R41, R42 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy
leads to the preparation of a compound of formula II
Figure US20150005488A1-20150101-C00036
wherein
R6 is hydrogen, or together with R7 is a double bond or an α or β-CH2 group;
R7 is hydrogen, C1-C4-alkyl, C1-C4-alkoxycarbonyl, C1-C4-thioacyl; or together with R6 is a double bond or an α or β-CH2 group;
R10 is hydrogen, methyl or ethyl;
R13 is methyl, or ethyl;
R15 is hydrogen, or C1-C4-alkyl, or together with R16 is a —CH2 group or a double bond; and
R16 is hydrogen or together with R15 is a —CH2 group or a double bond.
20. A process according to claim 19, wherein the compound of formula V is of formula Va
Figure US20150005488A1-20150101-C00037
wherein
R3 is hydrogen or
Figure US20150005488A1-20150101-C00038
R30, R31, R32 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy; and
R40, R41, R42 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy.
21. A process according to claim 19, wherein the compound of formula V is of formula Vb
Figure US20150005488A1-20150101-C00039
22. A process according to claim 19, wherein the reaction of a compound of formula V leads to the preparation of drospirenone.
23. A process according to claim 20, wherein the reaction of a compound of formula Va leads to the preparation of drospirenone.
24. A process according to claim 21, wherein the reaction of a compound of formula Va leads to the preparation of drospirenone.
25. A process for preparing a compound of formula II
Figure US20150005488A1-20150101-C00040
comprising oxidizing a compound of formula I
Figure US20150005488A1-20150101-C00041
which compound of formula I is provided from a process where it was synthesized by the complete catalytic hydrogenation of the alkyne function of a compound of formula V
Figure US20150005488A1-20150101-C00042
and by removal of the benzylic protective group or groups,
wherein in the compounds of formulas I, II and V
R3 is hydrogen or
Figure US20150005488A1-20150101-C00043
R30, R31, R32 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy;
R5 is hydrogen, or hydroxyl or together with R6 can be a double bond;
R6 is hydrogen, or together with R5 or R7 is a double bond; or together with R7 is an α or β-CH2 group;
R7 is hydrogen, C1-C4-alkyl C1-C4-alkoxycarbonyl, C1-C4-thioacyl; or together with R6 is a double bond or an α or β-CH2 group;
R10 is hydrogen, methyl or ethyl;
R13 is methyl, or ethyl;
R15 is hydrogen, or C1-C4-alkyl, or together with R16 is a —CH2 group or a double bond;
R16 is hydrogen or together with R15 is a —CH2 group or a double bond, and
R40, R41, R42 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy.
26. A process according to claim 25, wherein a compound of formula I is provided from a process where it was synthesized by the complete catalytic hydrogenation of the alkyne function of a compound of formula Va
Figure US20150005488A1-20150101-C00044
wherein
R3 is hydrogen or
Figure US20150005488A1-20150101-C00045
R30, R31, R32 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy; and
R40, R41, R42 are, independently of one another, hydrogen, C1-C4-alkyl or C1-C4-alkoxy;
and by removal of the benzylic protective group or groups.
27. A process according to claim 25, which is for the preparation of a compound of formula IIa
Figure US20150005488A1-20150101-C00046
comprising oxidizing a compound of formula Ia
Figure US20150005488A1-20150101-C00047
which compound of formula Ia is provided from a process where it was synthesized by the complete catalytic hydrogenation of the alkyne function of a compound of formula Vb
Figure US20150005488A1-20150101-C00048
and by removal of the benzylic protective group.
28. A process according to claim 25, wherein the compound of formula II is drospirenone.
29. A process according to claim 26, wherein the compound of formula II is drospirenone.
US14/487,662 2007-06-28 2014-09-16 Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids Abandoned US20150005488A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/487,662 US20150005488A1 (en) 2007-06-28 2014-09-16 Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94676207P 2007-06-28 2007-06-28
DE102007030596A DE102007030596B3 (en) 2007-06-28 2007-06-28 Process for the preparation of 17- (3-hydroxypropyl) -17-hydroxysteroids
DE102007030596.8 2007-06-28
US12/147,828 US8853431B2 (en) 2007-06-28 2008-06-27 Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids
US14/487,662 US20150005488A1 (en) 2007-06-28 2014-09-16 Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/147,828 Continuation US8853431B2 (en) 2007-06-28 2008-06-27 Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids

Publications (1)

Publication Number Publication Date
US20150005488A1 true US20150005488A1 (en) 2015-01-01

Family

ID=40029248

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/147,828 Expired - Fee Related US8853431B2 (en) 2007-06-28 2008-06-27 Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids
US14/487,662 Abandoned US20150005488A1 (en) 2007-06-28 2014-09-16 Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/147,828 Expired - Fee Related US8853431B2 (en) 2007-06-28 2008-06-27 Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids

Country Status (26)

Country Link
US (2) US8853431B2 (en)
EP (1) EP2170926B1 (en)
JP (2) JP5643087B2 (en)
KR (1) KR101547365B1 (en)
CN (1) CN101743248B (en)
AR (1) AR067194A1 (en)
AU (1) AU2008267145B2 (en)
BR (1) BRPI0813214A2 (en)
CA (1) CA2690177C (en)
CL (1) CL2008001908A1 (en)
DE (1) DE102007030596B3 (en)
DK (1) DK2170926T3 (en)
ES (1) ES2514516T3 (en)
HK (1) HK1144822A1 (en)
HR (1) HRP20140938T1 (en)
IL (1) IL202205A (en)
PA (1) PA8786201A1 (en)
PE (1) PE20090485A1 (en)
PL (1) PL2170926T3 (en)
PT (1) PT2170926E (en)
RU (1) RU2466137C2 (en)
SI (1) SI2170926T1 (en)
TW (1) TWI437006B (en)
UY (1) UY31188A1 (en)
WO (1) WO2009000923A2 (en)
ZA (1) ZA201000636B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007030596B3 (en) 2007-06-28 2009-03-12 Bayer Schering Pharma Aktiengesellschaft Process for the preparation of 17- (3-hydroxypropyl) -17-hydroxysteroids
CN105566032B (en) * 2014-10-09 2017-12-22 中国石油化工股份有限公司 The selection hydrogenation technique of rich alkynes carbon four

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319154B2 (en) * 2005-07-21 2008-01-15 Bayer Schering Pharma Ag Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3, 17-dihydroxyandrostanes
US8227596B2 (en) * 2004-12-06 2012-07-24 Industriale Chimica S.R.L. Process for the preparation of drospirenone
US8841283B2 (en) * 2010-08-03 2014-09-23 Newchem S.P.A. Methods for the preparation of drospirenone and intermediates thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3113953A (en) * 1958-11-28 1963-12-10 Sterling Drug Inc Esters of 17alpha-(3-hydroxy-1-propinyl) androst-5-ene-3beta, 17beta-diol and their preparation
FR2429056A1 (en) * 1978-06-19 1980-01-18 Tournus Manuf Metallurg PROCESS FOR PRODUCING COMPOSITE STRIPS BY CONTINUOUS CASTING
DE3042136A1 (en) * 1980-11-03 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen METHOD FOR PRODUCING 3 (BETA), 7 (BETA) -DIHYDROXY- (DELTA) (UP ARROW) 5 (UP ARROW) STEROIDS
EP0075189B1 (en) * 1981-09-21 1985-08-28 Schering Aktiengesellschaft 3-beta,7-beta,15-alpha-trihydroxy-5-androsten-17-one, its 3,15-dipivalate, and its preparation
US5106995A (en) * 1989-05-05 1992-04-21 Isp Investments Inc. Production of lactones from diols
US5693280A (en) 1996-07-31 1997-12-02 Owens-Corning Fiberglas Technology, Inc. Method of producing organic fibers from a rotary process
DE19633685C1 (en) * 1996-08-12 1997-10-09 Schering Ag Production of drospirenone useful as steroidal agent
US6784170B2 (en) * 2000-02-11 2004-08-31 Sri International Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one
ITMI20040367A1 (en) * 2004-03-01 2004-06-01 Ind Chimica Srl PROCESS FOR THE PREPARATION OF DROSPIRENONE
HUE027858T2 (en) * 2005-07-21 2016-11-28 Bayer Pharma AG Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes
CN100480256C (en) * 2006-06-21 2009-04-22 上海迪赛诺医药发展有限公司 Method for synthesizing Drospirenone
DE102007030596B3 (en) 2007-06-28 2009-03-12 Bayer Schering Pharma Aktiengesellschaft Process for the preparation of 17- (3-hydroxypropyl) -17-hydroxysteroids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227596B2 (en) * 2004-12-06 2012-07-24 Industriale Chimica S.R.L. Process for the preparation of drospirenone
US7319154B2 (en) * 2005-07-21 2008-01-15 Bayer Schering Pharma Ag Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3, 17-dihydroxyandrostanes
USRE44734E1 (en) * 2005-07-21 2014-01-28 Bayer Intellectual Property Gmbh Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes
US8841283B2 (en) * 2010-08-03 2014-09-23 Newchem S.P.A. Methods for the preparation of drospirenone and intermediates thereof

Also Published As

Publication number Publication date
SI2170926T1 (en) 2014-11-28
EP2170926A2 (en) 2010-04-07
HK1144822A1 (en) 2011-03-11
PL2170926T3 (en) 2014-12-31
AU2008267145B2 (en) 2013-10-24
US20090012286A1 (en) 2009-01-08
AU2008267145A1 (en) 2008-12-31
RU2466137C2 (en) 2012-11-10
KR101547365B1 (en) 2015-08-25
HRP20140938T1 (en) 2014-12-05
ZA201000636B (en) 2015-06-24
BRPI0813214A2 (en) 2014-12-23
RU2010102134A (en) 2011-08-10
CN101743248B (en) 2013-01-02
IL202205A (en) 2015-06-30
US8853431B2 (en) 2014-10-07
JP5643087B2 (en) 2014-12-17
UY31188A1 (en) 2009-01-30
AR067194A1 (en) 2009-09-30
ES2514516T3 (en) 2014-10-28
TWI437006B (en) 2014-05-11
PE20090485A1 (en) 2009-05-24
TW200918548A (en) 2009-05-01
CA2690177A1 (en) 2008-12-31
CA2690177C (en) 2015-09-15
EP2170926B1 (en) 2014-07-23
CN101743248A (en) 2010-06-16
PA8786201A1 (en) 2009-01-23
DE102007030596B3 (en) 2009-03-12
IL202205A0 (en) 2010-06-16
CL2008001908A1 (en) 2009-01-02
JP2014198724A (en) 2014-10-23
KR20100027158A (en) 2010-03-10
PT2170926E (en) 2014-10-13
JP2010531337A (en) 2010-09-24
WO2009000923A3 (en) 2009-04-23
JP5898731B2 (en) 2016-04-06
DK2170926T3 (en) 2014-10-13
WO2009000923A2 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
US8658788B2 (en) Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes
US20120214987A1 (en) Methods and compounds for preparing 3alpha-oxygen substituted steroids
US20090048218A1 (en) 17Beta-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE
JP5129899B2 (en) Process for the preparation of 17-hydroxy-6β, 7β; 15β, 16β-bismethylene-17α-pregne-4-en-3-one-21-carboxylic acid γ-lactone and important intermediates for this method
US8309712B2 (en) Industrial process for the preparation of 17-hydroxy-6beta,7beta;15beta, 16beta-bismethylene-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid y-lactone and key intermediates for this process
EP2253641A2 (en) A process for preparing drospirenone and intermediate thereof
US20150005488A1 (en) Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids
US8207150B2 (en) 17β-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative
US8334375B2 (en) Methods for the preparation of drospirenone
JP4749550B2 (en) 14β, 17α-hydroxymethylandrostane derivatives as androgens
EP1343806B1 (en) Methylene steroids as novel androgens
EP1556407A2 (en) Process and intermediates to prepare 17.beta.-hydroxy-7.alfa.-methyl-19-nor-17.alfa.-pregn-5(10)-en-20-yn-3-one
AU2002224923A1 (en) Methylene steroids as novel androgens

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAESELHOFF, CLAUS CHRISTIAN;PETERSEN, MIKE;REEL/FRAME:034091/0689

Effective date: 20141016

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION